Active	Status	Sponsor type	Region	Phase	Filter
3 Active 5 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tam, Lai Shan
NCT03623867: PsA Secukinumab XCT Structural Progression Study	Completed	4	40	RoW	Secukinumab, Cosentyx, Placebo	Chinese University of Hong Kong	Psoriatic Arthritis	09/22	09/22
NCT01768923: Early RA Vascular Randomised Controlled Study	Completed	N/A	120	RoW	SDAI remission, Minimal disease activity remission	Chinese University of Hong Kong	Early Rheumatoid Arthritis	06/22	06/22
NCT04324892: Effects of Achieving SDAI Remission on Joint Space Outcomes Progression in Early Rheumatoid Arthritis: an HR-pQCT Study	Active, not recruiting	N/A	110	RoW	Treat to target	Chinese University of Hong Kong	Rheumatoid Arthritis	01/24	01/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tam, Lai Shan
NCT03623867: PsA Secukinumab XCT Structural Progression Study	Completed	4	40	RoW	Secukinumab, Cosentyx, Placebo	Chinese University of Hong Kong	Psoriatic Arthritis	09/22	09/22
NCT01768923: Early RA Vascular Randomised Controlled Study	Completed	N/A	120	RoW	SDAI remission, Minimal disease activity remission	Chinese University of Hong Kong	Early Rheumatoid Arthritis	06/22	06/22
NCT04324892: Effects of Achieving SDAI Remission on Joint Space Outcomes Progression in Early Rheumatoid Arthritis: an HR-pQCT Study	Active, not recruiting	N/A	110	RoW	Treat to target	Chinese University of Hong Kong	Rheumatoid Arthritis	01/24	01/24